News Release Highlights:
1.Battery X Rebalancing Technologies successfully validates its next-generation battery rebalancing machine on a commercial electric truck battery that had experienced significant real-world imbalance, expanding functionality to include a Class 3 light-duty EV model.
2.Prototype 2.0 achieved 100% recovery of imbalance-related capacity loss and a 37.7% increase of the rated capacity, underscoring the machine's effectiveness on a significantly imbalanced battery pack.
3.Successful trial conducted on a significantly imbalanced battery pack provided by an authorized Canadian distributor of the electric truck, highlighting market interest and broader demand for cost-effective solutions to restore electric vehicle battery capacity and avoid costly full-pack replacements.
Read MoreXCF Global set to begin trading on Nasdaq under the ticker symbol "SAFX"
First publicly traded pure-play SAF producer in the United States
XCF Global's New Rise Reno facility is operational and revenue-generating, positioning XCF as a leading North American SAF producer poised for growth
Broadcasts Scheduled for 6/14, 6/21, and 6/28 at 6:30 PM EST on Bloomberg Television
Sponsored by The Sustainable Green Team's Waterless Garden™ and PetVivo Holdings' SPRYNG™
Read More
Lack of funding, corporate silence, and political interference threaten viable shelter plans amid a growing humanitarian crisis.
Read More
The RJ9 not only delivers a groundbreaking 900-mile total range, the highest of any production pickup, electric or gas, but does so while offering an unprecedented level of luxury, comfort, and driving intelligence never before seen in the truck category.
Read More
The Neutrino® Energy Group, an international consortium of scientists and engineers, is continuing to challenge the boundaries of decentralized energy with its groundbreaking development: the Neutrino Power Cube.
Read MoreAytu enters the over $22 billion United States prescription major depressive disorder ("MDD") market with the first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD.
EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, the incidence of sexual side effects experienced with EXXUA was comparable to placebo.
EXXUA is expected to serve as a major growth catalyst as Aytu continues to build value for shareholders; the Company anticipates launching EXXUA in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts.
EXXUA transaction financed by long-term, healthcare-focused institutional investors, including Aytu's largest shareholder Nantahala Capital Management, Stonepine Capital Management, Aytu management, and new institutional shareholders.
Read MoreWebUnited will host two exclusive Web3 workshops during ICANN 83 in Prague. Tailored for registrars, registries, and digital identity innovators, the sessions will take place on June 10 and June 11 from 16:00 to 18:00 CEST at the Grand Hotel Prague Towers, 24th Floor, followed by drinks, canapés, and skyline networking.
Read More
June 6, 2025: Article corrected to reflect award name as “Most Innovative Market Data Initiative”
Award-Winning Contract Performance Intelligence: PostSig's AI-Powered Platform Transforms Vendor Agreements into Actionable Insights, Ensuring Every Contract Delivers on Its Promise
Read More
Poll of 442 Healthcare Executives Highlights Four Key Workforce Issues Driving Adoption of AI, Virtual Care, and Automation Solutions Across 13 European Countries
Read More
Terrance Cole, the nominee for Administrator of the U.S. Drug Enforcement Administration (DEA), stands at a pivotal juncture with the opportunity to address longstanding issues related to the agency's handling of cannabis policy.
Read More
